Loading organizations...

§ Private Profile · South San Francisco, CA, USA
Structure Therapeutics is a technology company.
Structure Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative oral small molecule therapies. The firm leverages its advanced structure-based drug discovery platform to create treatments for chronic metabolic and cardiopulmonary conditions, with an initial focus on addressing obesity. This approach centers on precisely designing small molecule compounds to modulate specific biological targets, offering a novel modality for challenging diseases.
The company was founded in 2016 by Raymond C. Stevens, a distinguished pioneer in solving G protein-coupled receptor (GPCR) protein structures. Stevens’ deep scientific expertise and extensive background in structural biology provided the foundational insight for Structure Therapeutics, enabling the company to build a robust platform grounded in detailed molecular understanding. His vision was to translate this intricate structural knowledge into tangible therapeutic solutions.
Structure Therapeutics aims to serve patients afflicted with significant chronic conditions such as obesity and other metabolic and cardiopulmonary disorders. The company’s long-term vision is to become a leader in developing accessible, effective oral small molecule treatments that meaningfully improve patient outcomes and address substantial unmet medical needs worldwide. It continues to advance its pipeline with this forward-looking mission.
Structure Therapeutics has raised $175.0M across 4 funding rounds.
Structure Therapeutics has raised $175.0M in total across 4 funding rounds.
Structure Therapeutics is a clinical-stage biopharmaceutical company that uses structure-based small‑molecule drug design to create oral therapies for chronic metabolic and cardiopulmonary diseases, with a GPCR‑focused pipeline and several clinical‑stage programs[1][2].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Health Landscape
Quick Take & Future Outlook
Sources: company and profile pages summarizing Structure Therapeutics’ mission, platform, pipeline focus, founding year, headquarters, and team size[1][2].
Structure Therapeutics has raised $175.0M in total across 4 funding rounds.
Structure Therapeutics's investors include David E. Kroin, Piper Heartland Healthcare Capital, Mark Nathan Lampert, Qiming Venture Partners, Casdin Capital, Cormorant Asset Management, Eight Roads Ventures, F-Prime Capital, Hongshan Capital Group (Sequoia Capital China), Janus Henderson Investors, Lilly Asia Ventures, Monashee Investment Management.
Structure Therapeutics has raised $175.0M across 4 funding rounds. Most recently, it raised $33.0M Series B Extension in August 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2022 | $33M Series B Plus | David E. Kroin, Piper Heartland Healthcare Capital | — | Announced |
| Oct 1, 2021 | $100M Series B | Mark Nathan Lampert | Qiming Venture Partners, Casdin Capital, Cormorant Asset Management, Eight Roads Ventures, F Prime Capital, Hongshan Capital Group (Sequoia Capital China), Janus Henderson Investors, Lilly Asia Ventures, Monashee Investment Management, Sage Partners, Schr"dinger, Stork Capital, Surveyor Capital, Chen YU, Terra Magnum Capital Partners, TF Capital, Woodline Partners, WuXi AppTec | Announced |
| Mar 1, 2020 | $26M Series A | — | Qiming Venture Partners | Announced |
| Mar 1, 2019 | $16M Series A | — | Qiming Venture Partners | Announced |